<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS159097</article-id><article-id pub-id-type="doi">10.1101/2022.12.25.521784</article-id><article-id pub-id-type="archive">PPR589158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Weidenbacher</surname><given-names>Payton A.-B.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sanyal</surname><given-names>Mrinmoy</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Friedland</surname><given-names>Natalia</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Shaogeng</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Arunachalam</surname><given-names>Prabhu S.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Mengyun</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kumru</surname><given-names>Ozan S.</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>Mary Kate</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Fontenot</surname><given-names>Jane</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Shirreff</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Do</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Ya-Chen</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Vasudevan</surname><given-names>Gayathri</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Feinberg</surname><given-names>Mark B.</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Villinger</surname><given-names>Francois J.</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Hanson</surname><given-names>Carl</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Joshi</surname><given-names>Sangeeta B.</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Volkin</surname><given-names>David B.</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Pulendran</surname><given-names>Bali</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A9">9</xref><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Peter S.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A11">11</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><aff id="A1"><label>1</label>Sarafan ChEM-H, Stanford University, Stanford, CA, USA</aff><aff id="A2"><label>2</label>Department of Chemistry, Stanford University, Stanford, CA, USA</aff><aff id="A3"><label>3</label>Department of Biochemistry, School of Medicine, Stanford University, Stanford, CA, USA</aff><aff id="A4"><label>4</label>Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA</aff><aff id="A5"><label>5</label>Vaccine Analytics and Formulation Center, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA</aff><aff id="A6"><label>6</label>California Department of Public Health, Richmond, CA, USA</aff><aff id="A7"><label>7</label>New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA</aff><aff id="A8"><label>8</label>IAVI, New York, NY, USA</aff><aff id="A9"><label>9</label>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA</aff><aff id="A10"><label>10</label>Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA</aff><aff id="A11"><label>11</label>Chan Zuckerberg Biohub, San Francisco, California 94158, United States</aff></contrib-group><author-notes><corresp id="CR1"><label>*</label>Corresponding author (<email>kimpeter@stanford.edu</email>)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>29</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>26</day><month>12</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ∼one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly booster vaccine, and as a primary vaccine for pediatric use including in infants.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">The COVID-19 pandemic was met with record-breaking vaccine development speed,<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref></sup> and widespread vaccination is estimated to have prevented over 14 million deaths in the first year of implementation.<sup><xref ref-type="bibr" rid="R3">3</xref></sup> Nonetheless, there remains an urgent public health need for vaccine interventions. First, as of May, 2022, the WHO estimates that almost one billion people globally remain unvaccinated against SARS-CoV-2.<sup><xref ref-type="bibr" rid="R4">4</xref></sup> Second, affordability continues to be an obstacle to global vaccine accessibility, including the cost of low-temperature storage and transport.<sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref></sup> Third, the protection against infection provided by vaccine-induced or infection-induced immunity wanes with time, which has led to frequent booster vaccine doses.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> Fourth, SARS-CoV-2 variants of concern (VOCs) capable of evading natural or vaccine-induced humoral immunity continue to emerge.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> Finally, as SARS-CoV-2 becomes endemic, worldwide immunization of the pediatric population, including of infants, remains an unmet need.<sup><xref ref-type="bibr" rid="R9">9</xref></sup></p><p id="P3">Protein nanoparticle vaccines, compared to isolated protein subunits, are more readily taken up by antigen-presenting dendritic cells<sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref></sup> and the multivalent presentation of the antigen facilitated by the nanoparticles promotes receptor clustering and subsequent activation of B cells.<sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup> Indeed, candidate ferritin-based nanoparticle vaccines have shown robust humoral immune responses against SARS-CoV-2<sup><xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R16">16</xref></sup> and other viral glycoproteins,<sup><xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R21">21</xref></sup> including showing safety and efficacy in clinical trials.<sup><xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R22">22</xref></sup> Previously, we introduced a protein nanoparticle-based vaccine candidate, SΔC-Fer, which displays a truncated form of the prefusion SARS-CoV-2 spike-protein ectodomain trimer from the Wuhan-1 isolate on self-assembling <italic>Heliobacter pylori</italic> ferritin nanoparticles.<sup><xref ref-type="bibr" rid="R14">14</xref></sup> SΔC-Fer contains a mutated furin cleavage site and the 2-proline (2P)<sup><xref ref-type="bibr" rid="R23">23</xref></sup> prefusion-stabilizing substitutions found in the FDA-approved SARS-CoV-2 mRNA vaccines<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R24">24</xref></sup>. Importantly, SΔC-Fer also contains a deletion of 70 amino acid residues from the C-terminus of the spike ectodomain. This deletion removes a highly flexible region that is not well resolved in cryo-EM structures<sup><xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R27">27</xref></sup>, and that contains immunodominant, linear (i.e., not conformational) epitopes frequently targeted by antibodies in convalescent COVID-19 plasma<sup><xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref></sup>. Removal of these immunodominant linear epitopes and multivalent presentation of the modified spike protein on a ferritin nanoparticle substantially improved the neutralizing potency of elicited antisera relative to other tested vaccines in mice<sup><xref ref-type="bibr" rid="R14">14</xref></sup>.</p><p id="P4">Here, we introduce an updated version of SΔC-Fer, called Delta-C70-Ferritin-HexaPro or DCFHP. We supplemented the 2P stabilizing substitutions with four previously described<sup><xref ref-type="bibr" rid="R26">26</xref></sup> proline substitutions to create a six-proline substituted (HexaPro) version of the vaccine. Previous work has shown that the HexaPro SARS-CoV-2 spike protein has increased stability and expression relative to the 2P version<sup><xref ref-type="bibr" rid="R26">26</xref></sup>. We found that DCFHP is more stable to thermal denaturation than SΔC-Fer. In addition, we show that DCFHP can be generated in a Chinese hamster ovary (CHO) cell line at levels exceeding 2 grams per liter.</p><p id="P5">Our vaccine formulation, DCFHP-alum, consists of DCFHP antigen formulated with aluminum hydroxide (Alhydrogel™, referred to herein as alum) as the only adjuvant.<sup><xref ref-type="bibr" rid="R30">30</xref></sup> Aluminum salt adjuvants are the most commonly used adjuvant in human vaccines licensed by the FDA and regulatory agencies worldwide, and have been administered to billions of individuals over the past 90 years<sup><xref ref-type="bibr" rid="R31">31</xref>–<xref ref-type="bibr" rid="R33">33</xref></sup>. Moreover, aluminum salt adjuvants are currently used in infant vaccines against hepatitis B, diphtheria-tetanus-pertussis (DTaP), Haemophilus influenzae type b (Hib), and pneumococcus infectious agents<sup><xref ref-type="bibr" rid="R34">34</xref></sup>, with an excellent safety profile.<sup><xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R36">36</xref></sup></p><p id="P6">We show here that DCFHP-alum elicits a robust and durable immune response in mice against SARS-CoV-2 VOCs. Additionally, we demonstrate that DCFHP-alum remains stable at temperatures ranging from 4°C to 37°C for at least 14 days, as assessed by immunization studies in mice. Thus, we anticipate that local distribution of the DCFHP-alum vaccine could be feasible without refrigeration.</p><p id="P7">Finally, we demonstrate that a two-dose intramuscular immunization regimen in rhesus macaques with DCFHP-alum elicits antisera with durable, robust and broad neutralization of VOCs, including the Omicron subvariants BA.4/5<sup><xref ref-type="bibr" rid="R37">37</xref></sup> and BQ.1,<sup><xref ref-type="bibr" rid="R38">38</xref></sup> along with a balanced Th1 and Th2 immune response. Strikingly, these non-human primate (NHP) antisera also show robust and durable neutralization activity against the phylogenetically divergent SARS-CoV-1 pseudovirus.<sup><xref ref-type="bibr" rid="R39">39</xref></sup> Boosting these immunized NHPs after ∼1 year with a third dose of DCFHP-alum elicits a robust, broad-spectrum, anamnestic neutralizing antibody response. Taken together, these results suggest that DCFHP-alum may provide an affordable and effective solution to pediatric and worldwide vaccination against SARS-CoV-2 and present the possibility of an effective, once-yearly booster.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>Vaccine design and characterization</title><p id="P8">We sought to further optimize our ferritin-based nanoparticle vaccine, SΔC-Fer,<sup><xref ref-type="bibr" rid="R14">14</xref></sup> to generate DCFHP, which includes additional stabilizing proline residues to promote robust expression. DCFHP maintains the 2P substitutions<sup><xref ref-type="bibr" rid="R23">23</xref></sup> and deletion of 70 C-terminal spike ectodomain residues contained in SΔC-Fer,<sup><xref ref-type="bibr" rid="R14">14</xref></sup> but also incorporates four proline residue substitutions and a modification to the mutated furin cleavage site, as described in the HexaPro spike design<sup><xref ref-type="bibr" rid="R26">26</xref></sup> (<xref ref-type="fig" rid="F1">Fig 1A</xref>). As expected, DCFHP is expressed at higher levels than SΔC-Fer following transient transfection in Expi293F cells (<xref ref-type="supplementary-material" rid="SD1">SI Fig 1A-B</xref>). SDS-PAGE analysis of purified DCFHP showed the expected monomeric molecular weight of ∼160kDa (<xref ref-type="fig" rid="F1">Fig 1B</xref>). Additionally, size-exclusion chromatography coupled with multiangle light scattering (SEC-MALS) analysis shows that the nanoparticle has a molecular weight (∼3.4MDa) consistent with a ferritin-based nanoparticle displaying eight copies of the SARS-CoV-2 spike ectodomain trimer (<xref ref-type="fig" rid="F1">Fig 1C</xref>). Differential scanning fluorimetry (DSF) experiments indicate that thermal denaturation of DCFHP occurs at higher temperatures compared to SΔC-Fer, and these changes are similar to those observed between the 2P and HexaPro variants of the spike trimer<sup><xref ref-type="bibr" rid="R26">26</xref></sup> (<xref ref-type="supplementary-material" rid="SD1">SI Fig 1C</xref>), suggesting that HexaPro mutations induce similar stabilizing effects in the context of the nanoparticle. Biolayer interferometry (BLI) binding of conformation-specific antibodies<sup><xref ref-type="bibr" rid="R40">40</xref>–<xref ref-type="bibr" rid="R43">43</xref></sup> indicates proper epitope presentation (<xref ref-type="supplementary-material" rid="SD1">SI Fig. 1D</xref>). Finally, single particle cryo-electron microscopy (cryo-EM) of DCFHP shows a multivalent particle displaying eight copies of the SARS-CoV-2 trimer arrayed radially from a ferritin core (<xref ref-type="fig" rid="F1">Fig 1D</xref>, <xref ref-type="supplementary-material" rid="SD1">SI Fig. E-F</xref>), as was observed previously with SΔC-Fer.<sup><xref ref-type="bibr" rid="R14">14</xref></sup> Collectively, these data suggest that the spike component of DCFHP maintains the same native conformation as in SΔC-Fer, with increased stability and expression levels conferred by the HexaPro substitutions.</p><p id="P9">Finally, mice immunized with either SΔC-Fer or DCFHP, adjuvanted with a high dose of alum and CpG, showed highly robust and similar immunogenic profiles by enzyme-linked immunosorbent assay (ELISA) (<xref ref-type="supplementary-material" rid="SD1">SI Fig 2A</xref>) and pseudoviral neutralization assays<sup><xref ref-type="bibr" rid="R44">44</xref></sup> (<xref ref-type="fig" rid="F1">Fig 1E</xref>); see also<sup><xref ref-type="bibr" rid="R30">30</xref></sup>.</p></sec><sec id="S4"><title>DCFHP formulated with alum is highly immunogenic and stable at elevated temperatures</title><p id="P10">Given the robust immunogenicity of DCFHP formulated with alum and CpG, we hypothesized that the use of alum as the sole adjuvant for DCFHP (i.e., DCFHP-alum) might still elicit a robust response. Indeed, though the response was diminished compared to alum + CpG, DCFHP-alum elicited strong pseudoviral neutralizing titers of approximately 10<sup>4</sup> in mice (<xref ref-type="supplementary-material" rid="SD1">SI Fig 2B</xref>). Under these conditions, DCFHP is 100% bound to alum<sup>30</sup>.</p><p id="P11">To investigate the stability of the DCFHP-alum vaccine, samples were stored at 4°C, 27°C, or 37°C for varying times and the immunogenicity of these stored samples was evaluated in a single-dose mouse immunization study. Remarkably, the DCFHP-alum vaccine remained similarly immunogenic across all temperatures and storage periods, as measured in pseudoviral neutralization assays (<xref ref-type="fig" rid="F2">Fig 2</xref>). We conclude that DCFHP-alum is stable, as measured by mice immunogenicity studies, after storage for at least two weeks at 37°C.</p></sec><sec id="S5"><title>Stable expression of DCFHP increases yield and simplifies purification</title><p id="P12">To facilitate future manufacturing of DCFHP under good manufacturing practices (GMP) conditions, we next aimed to develop a high-producing stable mammalian cell line expressing DCFHP. To do so, multiple copies of a codon-optimized DCFHP gene were inserted into CHO-K1 cells using a Leap-In transposase at ATUM,<sup><xref ref-type="bibr" rid="R45">45</xref>,<xref ref-type="bibr" rid="R46">46</xref></sup> a bioengineering company (see <xref ref-type="supplementary-material" rid="SD1">Methods</xref>). As anticipated<sup><xref ref-type="bibr" rid="R47">47</xref></sup>, N-glycosylation profiles of these proteins expressed transiently in Expi293 versus stably in CHO cells differ<sup><xref ref-type="bibr" rid="R30">30</xref></sup> but they are similarly immunogenic in mice, as measured in pseudoviral neutralization assays<sup><xref ref-type="bibr" rid="R30">30</xref></sup>. Following preliminary analysis of expression in pooled cells, 125 single-cell clones were evaluated for high levels of cell growth and productivity, resulting in 24 lead clones (<xref ref-type="supplementary-material" rid="SD1">SI Fig 3A-C</xref>). Among these, we chose clones (<xref ref-type="supplementary-material" rid="SD1">SI Fig 4A-C</xref>) that showed favorable expression and nanoparticle assembly, as determined by SDS-PAGE, biolayer interferometry (BLI), and SEC-MALS (<xref ref-type="supplementary-material" rid="SD1">SI Fig 3A-C</xref>, respectively). In this manner, we identified five CHO-K1 stable cell clones (<xref ref-type="supplementary-material" rid="SD1">SI Fig 4A</xref>) that express DCFHP at a high nanoparticle:monomer ratio (<xref ref-type="supplementary-material" rid="SD1">SI Fig 4B</xref>), with expected stability (<xref ref-type="supplementary-material" rid="SD1">SI Fig 4C</xref>), and exceptional yield (&gt;2 g/L, <xref ref-type="fig" rid="F4">Fig 4A</xref>).</p><p id="P13">Additionally, we were able to optimize the purification of the nanoparticles over our previous method<sup><xref ref-type="bibr" rid="R14">14</xref></sup>. The CHO cell-derived supernatant was supplemented to 200mM sodium chloride and flowed over a HiTrapQ anion-exchange column. The nanoparticle-containing flowthrough was concentrated and subjected to size exclusion chromatography purification (see <xref ref-type="supplementary-material" rid="SD1">Methods</xref>). These changes enabled rapid and simplified nanoparticle purification, with increased yield, while maintaining high overall purity.</p></sec><sec id="S6"><title>DCFHP-alum is robustly immunogenic in non-human primates (NHPs)</title><p id="P14">Encouraged by results demonstrating that sera from mice immunized with DCFHP-alum showed potent neutralizing activity against SARS-CoV-2 pseudovirus, we sought to investigate the immunogenicity of the DCFHP-alum vaccine in NHPs. DCFHP purified from engineered CHO-K1 cells was used for the immunization of ten male rhesus macaques, aged between 3 and 9 years (<xref ref-type="supplementary-material" rid="SD1">SI Table 1</xref>). The ten NHPs were divided into two groups to test the effect of a short and a long gap between the primary and booster doses. Longer gaps have been found to produce more robust immune responses in other vaccines.<sup><xref ref-type="bibr" rid="R48">48</xref></sup></p><p id="P15">We primed both NHP groups on day 0 and boosted at either day 21 (group A) or day 92 (group B) (<xref ref-type="fig" rid="F3">Fig 3A</xref> and <xref ref-type="supplementary-material" rid="SD1">SI Table 2</xref>). DCFHP-alum elicited a neutralizing immune response 21 days after a single immunization in both groups (<xref ref-type="fig" rid="F3">Fig 3B</xref>). While the response was substantially improved following a booster dose in both groups, the delayed boost elicited better neutralizing antisera, as assessed 14 days post boost (<xref ref-type="fig" rid="F3">Fig 3C and D</xref>; <xref ref-type="supplementary-material" rid="SD1">SI Table 3</xref>); on average, group B showed approximately a 4-fold increased neutralizing response relative to group A against divergent VOCs. Remarkably, DCFHP-alum vaccination of NHPs also elicits robust neutralization of pseudotyped SARS-CoV-1 (<xref ref-type="fig" rid="F3">Fig 3C and D</xref>), which is distant from SARS-CoV-2 on the betasarbecovirus phylogenetic tree.<sup><xref ref-type="bibr" rid="R39">39</xref></sup></p><p id="P16">When tested against authentic SARS-CoV-2 virus, consistent with the results in pseudoviral assays, sera from the NHPs showed neutralization against the Wuhan-1 virus and VOCs (<xref ref-type="fig" rid="F3">Fig 3E</xref>). Notably, a ferritin-based SARS-CoV-2 vaccine candidate that elicits similar neutralizing titers to those described here has been shown to confer protection in hamster<sup><xref ref-type="bibr" rid="R49">49</xref></sup> and NHP challenge models.<sup><xref ref-type="bibr" rid="R16">16</xref></sup></p></sec><sec id="S7"><title>Long-lived immune responses in non-human primates</title><p id="P17">We further investigated the durability of the vaccine-induced neutralizing responses elicited in groups A and B (<xref ref-type="fig" rid="F4">Fig 4A-D</xref>, <xref ref-type="supplementary-material" rid="SD1">SI Fig 5</xref>, <xref ref-type="supplementary-material" rid="SD1">SI Table 2</xref>). Notably, all NHPs maintained a neutralizing antiserum response against the Wuhan-1 pseudovirus persisting for at least 250 days (<xref ref-type="fig" rid="F4">Fig 4A and C</xref>). Similarly, albeit more modestly, most animals in group B retained detectable neutralizing potency against BA.4/5 and the sequence-divergent SARS-CoV-1 out to ∼one year (<xref ref-type="fig" rid="F4">Fig 4D</xref> and <xref ref-type="supplementary-material" rid="SD1">SI Fig 5B</xref>), with titers generally higher than seen in group A (<xref ref-type="fig" rid="F4">Fig 4B and D</xref> and <xref ref-type="supplementary-material" rid="SD1">SI Fig 5A</xref> and <xref ref-type="supplementary-material" rid="SD1">B</xref>).</p><p id="P18">Simple modeling suggests a biphasic decay of neutralizing activity against Wuhan-1 pseudovirus following the boost for group A (days 35 - 337) with an initial, fast-phase (half-life of ∼5 weeks) followed by a slow-phase (half-life of several years) (<xref ref-type="fig" rid="F4">Fig 4</xref>, <xref ref-type="supplementary-material" rid="SD1">SI Fig 6B</xref> and <xref ref-type="supplementary-material" rid="SD1">SI Table 4</xref>). The fast-phase accounts for approximately 50% of the total decay (<xref ref-type="supplementary-material" rid="SD1">SI Fig 6B</xref> and <xref ref-type="supplementary-material" rid="SD1">SI Table 4</xref>). Simple modeling of these data with a single-phase decay shows a half-life of ∼one year, with a poorer fit than for biphasic decay (<xref ref-type="supplementary-material" rid="SD1">SI Fig 6A</xref> and <xref ref-type="supplementary-material" rid="SD1">SI Table 4</xref>). Similar trends are seen following the boost for group B (days 106 - 337), although with greater variability, presumably because our long-term data for group B is sparse (<xref ref-type="supplementary-material" rid="SD1">SI Table 4</xref>). In either case, a substantial portion of the serum neutralizing activity appears to decay very slowly with time following immunization of NHPs with DCFHP-alum.</p><p id="P19">To explicitly test the potential of DCFHP-alum as an annual vaccine, we gave a second boost to all NHPs on day 381. Animals in both groups A and B showed a strong anamnestic immune response with average NT<sub>50</sub> values against Wuhan-1, BA.4/5, SARS-CoV-1, and BQ.1 of approximately 10<sup>4</sup>, 10<sup>3.5</sup>, 10<sup>3</sup>, and 10<sup>3</sup> respectively (<xref ref-type="fig" rid="F5">Fig 5A-H</xref>, data for BQ.1.1 shown in <xref ref-type="supplementary-material" rid="SD1">SI Fig 7</xref>). The responses for the animals in group A is particularly striking given that their responses had generally waned prior to the second boost (compare <xref ref-type="fig" rid="F4">Fig. 4A and B</xref> and <xref ref-type="supplementary-material" rid="SD1">SI Fig 5A</xref> to <xref ref-type="fig" rid="F5">Fig. 5 A-C</xref>).</p><p id="P20">As seen previously for with immune responses with protein-based vaccines in a naive population,<sup><xref ref-type="bibr" rid="R50">50</xref></sup> we observed a dominant CD4+ T cell response with no detectable CD8+ T cell response. In both groups, DCFHP-alum elicited a balanced distribution of Th1 and Th2 CD4+ T cells (<xref ref-type="fig" rid="F6">Fig 6A-D</xref>, and <xref ref-type="supplementary-material" rid="SD1">SI Fig. 8</xref>). This response was similar to those reported for previous COVID-19 nanoparticle vaccines and with other adjuvant formulations.<sup>50</sup> Importantly, we detected responses from peptides derived not only from the original Wuhan-1 strain (<xref ref-type="fig" rid="F6">Fig 6A and C</xref>), but also from the Omicron BA.1 strain (<xref ref-type="fig" rid="F6">Fig 6B and D</xref>), suggesting responses targeting conserved T cell epitopes.</p></sec></sec><sec id="S8" sec-type="discussion"><title>Discussion</title><p id="P21">Our DCFHP-alum vaccine candidate, despite being based solely on the ancestral Wuhan-1 sequence, can elicit a robust, broad-spectrum neutralizing antiserum response in NHPs against SARS-CoV-2 VOCs, as well as against SARS-CoV-1, that is durable for &gt;250 days. These findings challenge the notion that bivalent vaccines are required to address the COVID-19 pandemic. In addition, while there is continued discussion surrounding annual COVID-19 vaccine boosters,<sup><xref ref-type="bibr" rid="R51">51</xref>–<xref ref-type="bibr" rid="R53">53</xref></sup> little to no work has been done to test the capacity of vaccines to elicit neutralizing antibody responses with durability of ∼one year and to elicit a subsequent response following an annual booster dose. Our results show that DCFHP-alum can elicit durable, broad-spectrum neutralizing antisera (including against BA.4/5, BQ.1, and SARS-CoV-1) in NHPs. We also show that a robust, anamnestic response can be elicited following a second boost after ∼one year.</p><p id="P22">Several studies of COVID-19 vaccines have established that a cell-culture pseudovirus neutralizing titer of ∼10<sup>2</sup> translates into human vaccine efficacy against symptomatic disease of ∼90%.<sup><xref ref-type="bibr" rid="R52">52</xref>–<xref ref-type="bibr" rid="R56">56</xref></sup> In addition, clinical trials have established a correlation between anti-SARS-CoV-2 monoclonal antibody levels (i.e., humoral immunity alone) and protection from COVID-19.<sup><xref ref-type="bibr" rid="R57">57</xref>,<xref ref-type="bibr" rid="R58">58</xref></sup> Indeed, SARS-CoV-2 variant booster vaccines have been accepted by the FDA and EMA for emergency use authorization using neutralizing antibody titer as a correlate of protection.<sup><xref ref-type="bibr" rid="R59">59</xref>,<xref ref-type="bibr" rid="R60">60</xref></sup></p><p id="P23">Accordingly, if our NHP results are reproduced in clinical trials, we anticipate that DCFHP-alum could be widely used as a booster vaccine for individuals who have been previously vaccinated with other COVID-19 vaccines, and in unvaccinated individuals that have been previously infected with SARS-CoV-2. Together, these two categories encompass a large fraction of the world’s population. As such, DCFHP-alum would be an attractive annual vaccine that could circumvent the need for continual variant chasing.</p><p id="P24">We also envision that DCFHP-alum could enable global access to COVID-19 vaccination given its low projected cost of goods, high scale of production, and favorable broad-spectrum profile. Our results show that a DCFHP stably integrated CHO-based cell line could enable low-cost, large-scale production. Assuming a vaccine dose of &lt;100 micrograms and a purification yield of &gt;10%, we anticipate production of thousands of DCFHP vaccine doses per liter of engineered CHO-K1 cell culture. As well, the DCFHP-alum formulation is stable for at least two weeks at temperatures exceeding standard room temperature. Taken together, DCFHP-alum is an excellent candidate for development as a new COVID-19 vaccine, offering broad-spectrum protection, and providing the opportunity for global access without the cold chain distribution challenges encountered with other vaccines.<sup><xref ref-type="bibr" rid="R61">61</xref></sup></p><p id="P25">Finally, we anticipate the potential use of DCFHP-alum as an important primary vaccine in previously unvaccinated and uninfected individuals, especially in pediatric populations, including infants. Aluminum salt adjuvants are commonly used in infant vaccines and as part of routine childhood immunization schedules, and their excellent safety profile has been established over decades.<sup><xref ref-type="bibr" rid="R31">31</xref>–<xref ref-type="bibr" rid="R36">36</xref></sup> In infants and other DCFHP-alum vaccine recipients naïve to SARS-CoV-2 infection or vaccination, we would anticipate robust, cross-reactive responses similar to the naïve NHPs studied here. Since primary immunization of NHPs with DCFHP-alum provides remarkably broad protection against VOCs, DCFHP-alum may be an ideal way to establish initial immune imprinting<sup><xref ref-type="bibr" rid="R62">62</xref>–<xref ref-type="bibr" rid="R64">64</xref></sup> against SARS-CoV-2 in infants.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Information</label><media xlink:href="EMS159097-supplement-Supplementary_Information.pdf" mimetype="application" mime-subtype="pdf" id="d92aAdDbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S9"><title>Acknowledgments</title><p>We thank members of the Kim Lab for discussions, and Dr. Luciana Borio and Dr. Duo Xu for helpful comments on an earlier draft of this manuscript. S.T. acknowledges NIH NICHD grant K99HD104924 and the Merck fellowship from the Damon Runyon Cancer Research Foundation. The CryoEM microscopy work was performed at the Stanford-SLAC Cryo-EM Center (S2C2) supported by the NIH Common Fund Transformative High Resolution Cryo-Electron Microscopy program (U24 GM129541). We thank F. Krammer and F. Amanat for providing the SARS-CoV-2 RBD plasmids for protein production, and J. Bloom and A. Greaney for plasmids and cells related to viral neutralization assays. The findings and conclusions in this article are those of the author(s) and do not necessarily represent the views or opinions of the California Department of Public Health or the California Health and Human Services Agency. This work was supported by the Frank Quattrone &amp; Denise Foderaro Family Research Fund, the Chan Zuckerberg Biohub, the Stanford Innovative Medicines Accelerator, the Virginia &amp; D.K. Ludwig Fund for Cancer Research, and an NIH Director’s Pioneer Award (DP1AI158125) to P.S.K.</p></ack><fn-group><fn id="FN1" fn-type="conflict"><p id="P26"><underline><bold>Competing Interests</bold></underline></p><p id="P27">P.A.B.W., M.S., N.F., S.T. and P.S.K. are named as inventors on patent applications applied for by Stanford University and the Chan Zuckerberg Biohub on immunogenic coronavirus fusion proteins and related methods, which have been licensed to Vaccine Company, Inc. P.A.B.W. is an employee of, and P.S.K. is a co-founder of Vaccine Company, Inc.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polack</surname><given-names>FP</given-names></name><etal/></person-group><article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="pmcid">PMC7745181</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2439</fpage><lpage>2450</lpage><pub-id pub-id-type="pmcid">PMC7583697</pub-id><pub-id pub-id-type="pmid">33053279</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2027906</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>OJ</given-names></name><etal/></person-group><article-title>Global impact of the first year of COVID-19 vaccination: a mathematical modelling study</article-title><source>Lancet Infect Dis</source><year>2022</year><volume>22</volume><fpage>1293</fpage><lpage>1302</lpage><pub-id pub-id-type="pmcid">PMC9225255</pub-id><pub-id pub-id-type="pmid">35753318</pub-id><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00320-6</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrotri</surname><given-names>M</given-names></name><name><surname>Swinnen</surname><given-names>T</given-names></name><name><surname>Kampmann</surname><given-names>B</given-names></name><name><surname>Parker</surname><given-names>EPK</given-names></name></person-group><article-title>An interactive website tracking COVID-19 vaccine development</article-title><source>Lancet Glob Health</source><year>2021</year><volume>9</volume><fpage>e590</fpage><lpage>e592</lpage><pub-id pub-id-type="pmcid">PMC8049589</pub-id><pub-id pub-id-type="pmid">33667404</pub-id><pub-id pub-id-type="doi">10.1016/S2214-109X(21)00043-7</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acharya</surname><given-names>KP</given-names></name><name><surname>Ghimire</surname><given-names>TR</given-names></name><name><surname>Subramanya</surname><given-names>SH</given-names></name></person-group><article-title>Access to and equitable distribution of COVID-19 vaccine in low-income countries</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>54</fpage><pub-id pub-id-type="pmcid">PMC8047027</pub-id><pub-id pub-id-type="pmid">33854072</pub-id><pub-id pub-id-type="doi">10.1038/s41541-021-00323-6</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumru</surname><given-names>OS</given-names></name><etal/></person-group><article-title>Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies</article-title><source>Biologicals</source><year>2014</year><volume>42</volume><fpage>237</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">24996452</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>EG</given-names></name><etal/></person-group><article-title>Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>e84</fpage><pub-id pub-id-type="pmcid">PMC8522797</pub-id><pub-id pub-id-type="pmid">34614326</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2114583</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cele</surname><given-names>S</given-names></name><etal/></person-group><article-title>Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization</article-title><source>Nature</source><year>2022</year><volume>602</volume><fpage>654</fpage><lpage>656</lpage><pub-id pub-id-type="pmcid">PMC8866126</pub-id><pub-id pub-id-type="pmid">35016196</pub-id><pub-id pub-id-type="doi">10.1038/s41586-021-04387-1</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaslow</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Why vaccinate children against COVID-19?</article-title><source>Vaccine Insights</source><year>2022</year><volume>1</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.18609/vac.2022.32</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Nanoparticle vaccines</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">24295808</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Sagaseta</surname><given-names>J</given-names></name><name><surname>Malito</surname><given-names>E</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name><name><surname>Bottomley</surname><given-names>MJ</given-names></name></person-group><article-title>Self-assembling protein nanoparticles in the design of vaccines</article-title><source>Comput Struct Biotechnol J</source><year>2016</year><volume>14</volume><fpage>58</fpage><lpage>68</lpage><pub-id pub-id-type="pmcid">PMC4706605</pub-id><pub-id pub-id-type="pmid">26862374</pub-id><pub-id pub-id-type="doi">10.1016/j.csbj.2015.11.001</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>HG</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name><name><surname>Wheatley</surname><given-names>AK</given-names></name></person-group><article-title>Immunological basis for enhanced immunity of nanoparticle vaccines</article-title><source>Expert Rev Vaccines</source><year>2019</year><volume>18</volume><fpage>269</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">30707635</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>735</fpage><lpage>741</lpage><pub-id pub-id-type="pmcid">PMC7928838</pub-id><pub-id pub-id-type="pmid">33436524</pub-id><pub-id pub-id-type="doi">10.1126/science.abf6840</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>AE</given-names></name><etal/></person-group><article-title>A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice</article-title><source>ACS Cent Sci</source><year>2021</year><volume>7</volume><fpage>183</fpage><lpage>199</lpage><pub-id pub-id-type="pmcid">PMC7805605</pub-id><pub-id pub-id-type="pmid">33527087</pub-id><pub-id pub-id-type="doi">10.1021/acscentsci.0c01405</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>MG</given-names></name><etal/></person-group><article-title>SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity</article-title><source>Cell Rep</source><year>2021</year><volume>37</volume><elocation-id>110143</elocation-id><pub-id pub-id-type="pmcid">PMC8651551</pub-id><pub-id pub-id-type="pmid">34919799</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.110143</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>MG</given-names></name><etal/></person-group><article-title>A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates</article-title><source>Sci Transl Med</source><year>2022</year><volume>14</volume><elocation-id>eabi5735</elocation-id><pub-id pub-id-type="pmid">34914540</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanson</surname><given-names>KA</given-names></name><etal/></person-group><article-title>A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain</article-title><source>Sci Immunol</source><year>2020</year><volume>5</volume><pub-id pub-id-type="pmid">32358170</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sliepen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity</article-title><source>Retrovirology</source><year>2015</year><volume>12</volume><fpage>82</fpage><pub-id pub-id-type="pmcid">PMC4583754</pub-id><pub-id pub-id-type="pmid">26410741</pub-id><pub-id pub-id-type="doi">10.1186/s12977-015-0210-4</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yassine</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection</article-title><source>Nat Med</source><year>2015</year><volume>21</volume><fpage>1065</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">26301691</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanekiyo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>1090</fpage><lpage>1100</lpage><pub-id pub-id-type="pmcid">PMC4757492</pub-id><pub-id pub-id-type="pmid">26279189</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.043</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells</article-title><source>Immunity</source><year>2019</year><volume>50</volume><fpage>1305</fpage><lpage>1316</lpage><elocation-id>e1306</elocation-id><pub-id pub-id-type="pmcid">PMC6660903</pub-id><pub-id pub-id-type="pmid">30979688</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.010</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houser</surname><given-names>KV</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">35115706</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallesen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen</article-title><source>Proc Natl Acad Sci U S A</source><year>2017</year><volume>114</volume><fpage>E7348</fpage><lpage>E7357</lpage><pub-id pub-id-type="pmcid">PMC5584442</pub-id><pub-id pub-id-type="pmid">28807998</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1707304114</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>LA</given-names></name><etal/></person-group><article-title>An mRNA Vaccine against SARS-CoV-2 - Preliminary Report</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>1920</fpage><lpage>1931</lpage><pub-id pub-id-type="pmcid">PMC7377258</pub-id><pub-id pub-id-type="pmid">32663912</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2022483</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>281</fpage><lpage>292</lpage><elocation-id>e286</elocation-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id><pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Structure-based design of prefusion-stabilized SARS-CoV-2 spikes</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1501</fpage><lpage>1505</lpage><pub-id pub-id-type="pmcid">PMC7402631</pub-id><pub-id pub-id-type="pmid">32703906</pub-id><pub-id pub-id-type="doi">10.1126/science.abd0826</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="pmcid">PMC7164637</pub-id><pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamecnik</surname><given-names>CR</given-names></name><etal/></person-group><article-title>ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens</article-title><source>Cell Rep Med</source><year>2020</year><volume>1</volume><elocation-id>100123</elocation-id><pub-id pub-id-type="pmcid">PMC7513813</pub-id><pub-id pub-id-type="pmid">32995758</pub-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100123</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients</article-title><source>Cell Rep</source><year>2021</year><volume>34</volume><elocation-id>108915</elocation-id><pub-id pub-id-type="pmcid">PMC7953450</pub-id><pub-id pub-id-type="pmid">33761319</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108915</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumru</surname><given-names>OS</given-names></name><name><surname>Friedland</surname><given-names>N</given-names></name><name><surname>Sanyal</surname><given-names>M</given-names></name><name><surname>Hickey</surname><given-names>J</given-names></name><name><surname>Joshi</surname><given-names>R</given-names></name><name><surname>Weidenbacher</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>PS</given-names></name><name><surname>Joshi</surname><given-names>SB</given-names></name><name><surname>Volkin</surname><given-names>DB</given-names></name></person-group><article-title>Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines</article-title><source>Preparation</source><year>2022</year></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Gregorio</surname><given-names>E</given-names></name><name><surname>Tritto</surname><given-names>E</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name></person-group><article-title>Alum adjuvanticity: unraveling a century old mystery</article-title><source>Eur J Immunol</source><year>2008</year><volume>38</volume><fpage>2068</fpage><lpage>2071</lpage><pub-id pub-id-type="pmid">18651701</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Pasquale</surname><given-names>A</given-names></name><name><surname>Preiss</surname><given-names>S</given-names></name><name><surname>Tavares Da Silva</surname><given-names>F</given-names></name><name><surname>Garcon</surname><given-names>N</given-names></name></person-group><article-title>Vaccine Adjuvants: from 1920 to 2015 and Beyond</article-title><source>Vaccines (Basel)</source><year>2015</year><volume>3</volume><fpage>320</fpage><lpage>343</lpage><pub-id pub-id-type="pmcid">PMC4494348</pub-id><pub-id pub-id-type="pmid">26343190</pub-id><pub-id pub-id-type="doi">10.3390/vaccines3020320</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>HogenEsch</surname><given-names>H</given-names></name><name><surname>O’Hagan</surname><given-names>DT</given-names></name><name><surname>Fox</surname><given-names>CB</given-names></name></person-group><article-title>Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want</article-title><source>NPJ Vaccines</source><year>2018</year><volume>3</volume><fpage>51</fpage><pub-id pub-id-type="pmcid">PMC6180056</pub-id><pub-id pub-id-type="pmid">30323958</pub-id><pub-id pub-id-type="doi">10.1038/s41541-018-0089-x</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tritto</surname><given-names>E</given-names></name><name><surname>Mosca</surname><given-names>F</given-names></name><name><surname>De Gregorio</surname><given-names>E</given-names></name></person-group><article-title>Mechanism of action of licensed vaccine adjuvants</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>3331</fpage><lpage>3334</lpage><pub-id pub-id-type="pmid">19200813</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitkus</surname><given-names>RJ</given-names></name><name><surname>King</surname><given-names>DB</given-names></name><name><surname>Hess</surname><given-names>MA</given-names></name><name><surname>Forshee</surname><given-names>RA</given-names></name><name><surname>Walderhaug</surname><given-names>MO</given-names></name></person-group><article-title>Updated aluminum pharmacokinetics following infant exposures through diet and vaccination</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>9538</fpage><lpage>9543</lpage><pub-id pub-id-type="pmid">22001122</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baylor</surname><given-names>NW</given-names></name><name><surname>Egan</surname><given-names>W</given-names></name><name><surname>Richman</surname><given-names>P</given-names></name></person-group><article-title>Aluminum salts in vaccines--US perspective</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><issue>Suppl 3</issue><fpage>S18</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">12184360</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuekprakhon</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>2422</fpage><lpage>2433</lpage><elocation-id>e2413</elocation-id><pub-id pub-id-type="pmcid">PMC9181312</pub-id><pub-id pub-id-type="pmid">35772405</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2022.06.005</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.2010.2019.512891</elocation-id><pub-id pub-id-type="doi">10.1101/2022.10.19.512891</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaimes</surname><given-names>JA</given-names></name><name><surname>Andre</surname><given-names>NM</given-names></name><name><surname>Chappie</surname><given-names>JS</given-names></name><name><surname>Millet</surname><given-names>JK</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><article-title>Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop</article-title><source>J Mol Biol</source><year>2020</year><volume>432</volume><fpage>3309</fpage><lpage>3325</lpage><pub-id pub-id-type="pmcid">PMC7166309</pub-id><pub-id pub-id-type="pmid">32320687</pub-id><pub-id pub-id-type="doi">10.1016/j.jmb.2020.04.009</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X</given-names></name><etal/></person-group><article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</article-title><source>Emerg Microbes Infect</source><year>2020</year><volume>9</volume><fpage>382</fpage><lpage>385</lpage><pub-id pub-id-type="pmcid">PMC7048180</pub-id><pub-id pub-id-type="pmid">32065055</pub-id><pub-id pub-id-type="doi">10.1080/22221751.2020.1729069</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwer</surname><given-names>PJM</given-names></name><etal/></person-group><article-title>Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>643</fpage><lpage>650</lpage><pub-id pub-id-type="pmcid">PMC7299281</pub-id><pub-id pub-id-type="pmid">32540902</pub-id><pub-id pub-id-type="doi">10.1126/science.abc5902</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Structural basis for broad coronavirus neutralization</article-title><source>Nat Struct Mol Biol</source><year>2021</year><volume>28</volume><fpage>478</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">33981021</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cell entry mechanisms of SARS-CoV-2</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><fpage>11727</fpage><lpage>11734</lpage><pub-id pub-id-type="pmcid">PMC7260975</pub-id><pub-id pub-id-type="pmid">32376634</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2003138117</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>KHD</given-names></name><etal/></person-group><article-title>Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays</article-title><source>Viruses</source><year>2020</year><volume>12</volume><pub-id pub-id-type="pmcid">PMC7291041</pub-id><pub-id pub-id-type="pmid">32384820</pub-id><pub-id pub-id-type="doi">10.3390/v12050513</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balasubramanian</surname><given-names>S</given-names></name><etal/></person-group><article-title>Generation of High Expressing Chinese Hamster Ovary Cell Pools Using the Leap-In Transposon System</article-title><source>Biotechnol J</source><year>2018</year><volume>13</volume><elocation-id>e1700748</elocation-id><pub-id pub-id-type="pmid">29797786</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajendran</surname><given-names>S</given-names></name><etal/></person-group><article-title>Accelerating and de-risking CMC development with transposon-derived manufacturing cell lines</article-title><source>Biotechnol Bioeng</source><year>2021</year><volume>118</volume><fpage>2301</fpage><lpage>2311</lpage><pub-id pub-id-type="pmcid">PMC8252637</pub-id><pub-id pub-id-type="pmid">33704772</pub-id><pub-id pub-id-type="doi">10.1002/bit.27742</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croset</surname><given-names>A</given-names></name><etal/></person-group><article-title>Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells</article-title><source>J Biotechnol</source><year>2012</year><volume>161</volume><fpage>336</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">22814405</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect</article-title><source>J Infect Dis</source><year>2013</year><volume>208</volume><fpage>418</fpage><lpage>422</lpage><pub-id pub-id-type="pmcid">PMC3699006</pub-id><pub-id pub-id-type="pmid">23633407</pub-id><pub-id pub-id-type="doi">10.1093/infdis/jit180</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wuertz</surname><given-names>KM</given-names></name><etal/></person-group><article-title>A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>129</fpage><pub-id pub-id-type="pmcid">PMC8553838</pub-id><pub-id pub-id-type="pmid">34711815</pub-id><pub-id pub-id-type="doi">10.1038/s41541-021-00392-7</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arunachalam</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Adjuvanting a subunit COVID-19 vaccine to induce protective immunity</article-title><source>Nature</source><year>2021</year><volume>594</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">33873199</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JI</given-names></name><name><surname>Burbelo</surname><given-names>PD</given-names></name></person-group><article-title>Reinfection With SARS-CoV-2: Implications for Vaccines</article-title><source>Clin Infect Dis</source><year>2021</year><volume>73</volume><fpage>e4223</fpage><lpage>e4228</lpage><pub-id pub-id-type="pmcid">PMC7799323</pub-id><pub-id pub-id-type="pmid">33338197</pub-id><pub-id pub-id-type="doi">10.1093/cid/ciaa1866</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>1205</fpage><lpage>1211</lpage><pub-id pub-id-type="pmid">34002089</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>PW</given-names></name><name><surname>Gruppuso</surname><given-names>PA</given-names></name><name><surname>Adashi</surname><given-names>EY</given-names></name></person-group><article-title>Urgent Need for Next-Generation COVID-19 Vaccines</article-title><source>JAMA</source><year>2022</year><pub-id pub-id-type="pmid">36484995</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>PB</given-names></name><etal/></person-group><article-title>A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines</article-title><source>N Engl J Med</source><year>2022</year><pub-id pub-id-type="pmid">36507702</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Correlates of protection against SARS-CoV-2 in rhesus macaques</article-title><source>Nature</source><year>2021</year><volume>590</volume><fpage>630</fpage><lpage>634</lpage><pub-id pub-id-type="pmcid">PMC7906955</pub-id><pub-id pub-id-type="pmid">33276369</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-03041-6</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldblatt</surname><given-names>D</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Plotkin</surname><given-names>SA</given-names></name></person-group><article-title>Correlates of protection against SARS-CoV-2 infection and COVID-19 disease</article-title><source>Immunol Rev</source><year>2022</year><volume>310</volume><fpage>6</fpage><lpage>26</lpage><pub-id pub-id-type="pmcid">PMC9348242</pub-id><pub-id pub-id-type="pmid">35661178</pub-id><pub-id pub-id-type="doi">10.1111/imr.13091</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>P</given-names></name><etal/></person-group><article-title>Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers</article-title><source>medRxiv</source><year>2022</year><elocation-id>2022.2010.2018.22281172</elocation-id><pub-id pub-id-type="doi">10.1101/2022.10.18.22281172</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadler</surname><given-names>E</given-names></name><etal/></person-group><article-title>Monoclonal antibody levels and protection from COVID-19</article-title><source>medRxiv</source><year>2022</year><elocation-id>2022.2011.2022.22282199</elocation-id><pub-id pub-id-type="doi">10.1101/2022.11.22.22282199</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><collab>U.S Department of Health and Human Services Food and Drug Administration</collab><article-title>Emergency Use Authorization for Vaccines to Prevent COVID-19</article-title><source>Guidance for Industry</source><year>2022</year></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><collab>European Medicines Agency Committee for Human Medicinal Products (CHMP)</collab><article-title>Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2</article-title><year>2022</year></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uddin</surname><given-names>MN</given-names></name><name><surname>Roni</surname><given-names>MA</given-names></name></person-group><article-title>Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines</article-title><source>Vaccines (Basel)</source><year>2021</year><volume>9</volume><pub-id pub-id-type="pmcid">PMC8473088</pub-id><pub-id pub-id-type="pmid">34579270</pub-id><pub-id pub-id-type="doi">10.3390/vaccines9091033</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roltgen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>1025</fpage><lpage>1040</lpage><elocation-id>e1014</elocation-id><pub-id pub-id-type="pmcid">PMC8786601</pub-id><pub-id pub-id-type="pmid">35148837</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.018</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodda</surname><given-names>LB</given-names></name><etal/></person-group><article-title>Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>1588</fpage><lpage>1601</lpage><elocation-id>e1514</elocation-id><pub-id pub-id-type="pmcid">PMC8926873</pub-id><pub-id pub-id-type="pmid">35413241</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2022.03.018</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guthmiller</surname><given-names>JJ</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><article-title>Harnessing immune history to combat influenza viruses</article-title><source>Curr Opin Immunol</source><year>2018</year><volume>53</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">29890370</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>DCFHP design and validation.</title><p>(A) DCFHP schematic showing the modifications made to convert SΔC-Fer into DCFHP in red. Receptor binding domain (RBD), N-terminal domain (NTD), S1/S2 cleavage site, S2’ cleavage site, fusion peptide (FP), heptad repeat 1 (HR1), as annotated. (B) SDS-PAGE gel showing purified DCFHP running as a monomer at the anticipated kDa molecular weight (ladder, shown left). (C) UV (yellow) and light scattering (grey) traces determined from SEC-MALS shows a homogenous nanoparticle peak with approximate molecular weight (dashed line) of 3.4MDa. (D) 3D reconstructed cryo-EM density maps of DCFHP, refined with octahedral symmetry. (E) Similar robust neutralization of Wuhan-1 SARS-CoV-2 pseudovirus with day 21 serum from mice immunized with either SΔC-Fer or DCHFP formulated with 500 µg alum and 20 µg CpG 1826, following a single immunization. Neutralization titers were assessed in a HeLa cell line expressing ACE2 and TMPRSS2. Data for 10 mice are presented as geometric mean titer and standard deviation. Assay limit of quantitation (LOQ) is shown as a dotted horizontal line.</p></caption><graphic xlink:href="EMS159097-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Formulated DCFHP-alum is thermostable up to 37 °C for 14 days. Neutralization titers against Wuhan-1 SARS-CoV-2 pseudovirus for serum obtained from individual animals 21 days following immunization with DCFHP-alum (10 µg DCFHP with 150 µg alum) that had been stored at a range of temperatures (bottom) for either 7 days or 14 days, compared to freshly formulated DCFHP-alum (left, black circles). Assay limits of quantitation is shown as a dotted horizontal line.</p></caption><graphic xlink:href="EMS159097-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>DCFHP-alum immunized NHPs elicit cross-reactive neutralizing responses.</title><p>(A) Immunization scheme for NHPs immunized in either group A or group B with a 50 µg dose of DCFHP formulated with 750 µg alum (<xref ref-type="supplementary-material" rid="SD1">SI Table 2</xref>). Arrows indicate days of immunization. (B) Pseudoviral neutralization (plotted as the log of the neutralizing titer (reciprocal serum dilution)) of Wuhan-1 SARS-CoV-2 from NHP serum obtained 21 days following initial immunization are similar between groups A and B. (C) Cross-reactive pseudoviral neutralization by serum from NHPs isolated 14 days post boost. Means and standard deviations for biological replicates are plotted and noted for each animal (n = number of biological replicates). (D) As in panel C for group B. (E) Limited dilution, neutralization values for authentic SARS-CoV-2 VOCs for serum samples obtained 14 days post-boost. NHP identification provided correlate with <xref ref-type="supplementary-material" rid="SD1">SI Table 1</xref>. Assay limits of quantitation indicated by horizontal dotted line.</p></caption><graphic xlink:href="EMS159097-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>DCFHP-alum immunized NHPs elicit long-lived immunity against both Wuhan-1 and BA.4/5 pseudoviruses.</title><p>(A) Serum neutralizing titers were monitored over 337 days against Wuhan-1 SARS-CoV-2 pseudovirus for animals in group A; days of prime and boost indicated with arrows. (B) As in panel A but against BA.4/5 pseudovirus. (C) and (D) as in panels A and B but with group B NHPs, respectively. Averages and standard deviations for replicate neutralization assays are shown; for panels A-D: n = 3, n = 4, n = 2 and n = 3, respectively. NHP identification provided correlate with <xref ref-type="supplementary-material" rid="SD1">SI Table 1</xref>. Assay limits of quantitation indicated by horizontal dotted lines.</p></caption><graphic xlink:href="EMS159097-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Robust serum neutralizing anamnestic responses following a second booster of DCFHP-alum after ∼one year in NHPs.</title><p>(A) Pseudovirus neutralization against Wuhan-1 (A), BA.4/5 (B), SARS-1 (C), or BQ.1 (D) by antisera from NHPs in group A following a boost at day 381. Days shown on x axis. (E)-(H) as in panels A-D but with NHPs in group B. NHP identification provided correlate with <xref ref-type="supplementary-material" rid="SD1">SI table 1</xref>. (n = 2 biological replicates throughout). Assay limits of quantitation indicated by horizontal dotted lines.</p></caption><graphic xlink:href="EMS159097-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>DCFHP-alum immunized NHPs shows a balanced distribution of Th1 and Th2 CD4+ T cell responses.</title><p>T cells from animals in group A, isolated on the day shown on the x-axis, were stimulated with a peptide pool derived from Wuhan-1 (A) or Omicron BA.1 (B) spike protein and Th1 (top) and Th2 (bottom) cytokines were measured using flow cytometry (<xref ref-type="supplementary-material" rid="SD1">SI Fig. 8</xref>). Percent of CD4+ T cells that express either Th1 (IL-2,IFNγ or TNFα) (yellows and reds) or Th2 (IL-4) (greys) cytokines following stimulation shows both are elicited following vaccination with DCFHP-alum. Arrow denotes day of boost. (C)-(D) As in panels A-B but with NHPs in group B. NHP identification provided correlate with <xref ref-type="supplementary-material" rid="SD1">SI table 1</xref>.</p></caption><graphic xlink:href="EMS159097-f006"/></fig></floats-group></article>